Ajanta Pharma Ltd (AJPH.NS)
19 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||1979||Non-Executive Chairman of the Board|
|60||1979||Vice Chairman of the Board|
|46||2014||Compliance Officer, Senior General Manager - Legal, Company Secretary|
|39||2013||Joint Managing Director, Director|
|43||2000||Managing Director, Director|
- BRIEF-Ajanta Pharma's Vice-Chairman Purushottam B. Agrawal Resigns
- BRIEF-India's Ajanta Pharma launches clonidine hydrochloride extended release tablets in U.S.
- BRIEF-India's Ajanta Pharma Sept-qtr consol profit rises marginally
- BRIEF-India's Ajanta Pharma gets final approval for Entacapone tablets from U.S. FDA
- BRIEF-Ajanta Pharma says U.S. unit launches eletriptan hydrobromide tablets